Trevi Therapeutics (TRVI) Enterprise Value (2018 - 2026)
Trevi Therapeutics' quarterly Enterprise Value came in at -$171.8 million in Q1 2026, down 66.36% year-on-year from -$510.7 million in Q1 2025, and up 8.75% quarter-over-quarter from -$188.3 million in Q4 2025.
Trevi Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$171.8 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 66.36% year-over-year to -$171.8 million; the trailing twelve-month figure through Mar 2026 stood at -$171.8 million (down 66.36% YoY), and the FY2025 full-year result was -$188.3 million, down 74.93% from the prior year.
- Enterprise Value for Q1 2026 stood at -$171.8 million, up from -$188.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$11.6 million in Q1 2022, with the low at -$203.9 million in Q2 2025.
- Average Enterprise Value over 5 years is -$111.2 million, with a median of -$103.3 million recorded in 2025.
- Year-over-year, Enterprise Value jumped 72.12% in 2022 and plunged 860.03% in 2023.
- Tracing TRVI's Enterprise Value over 5 years: stood at -$120.5 million in 2022, then soared by 31.15% to -$83.0 million in 2023, then retreated by 29.71% to -$107.6 million in 2024, then tumbled by 74.93% to -$188.3 million in 2025, then increased by 8.75% to -$171.8 million in 2026.
- The last three Enterprise Value figures came in at -$171.8 million (Q1 2026), -$188.3 million (Q4 2025), and -$194.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -171.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -171.78 Mn |
| Dec 31, 2025 | -188.26 Mn |
| Sep 30, 2025 | -194.93 Mn |
| Jun 30, 2025 | -203.89 Mn |
| Mar 31, 2025 | -103.26 Mn |
| Dec 31, 2024 | -107.62 Mn |
| Sep 30, 2024 | -65.49 Mn |
| Jun 30, 2024 | -69.50 Mn |
| Mar 31, 2024 | -72.82 Mn |
| Dec 31, 2023 | -82.97 Mn |
| Sep 30, 2023 | -88.87 Mn |
| Jun 30, 2023 | -94.15 Mn |
| Mar 31, 2023 | -111.26 Mn |
| Dec 31, 2022 | -120.51 Mn |
| Sep 30, 2022 | -125.60 Mn |
| Jun 30, 2022 | -77.86 Mn |
| Mar 31, 2022 | -11.59 Mn |
| Dec 31, 2021 | -36.80 Mn |
| Sep 30, 2021 | -29.30 Mn |
| Jun 30, 2021 | -36.40 Mn |
| Mar 31, 2021 | -41.57 Mn |
| Dec 31, 2020 | -45.00 Mn |
| Sep 30, 2020 | -53.29 Mn |
| Jun 30, 2020 | -44.18 Mn |
| Mar 31, 2020 | -52.64 Mn |
| Dec 31, 2019 | -57.31 Mn |
| Sep 30, 2019 | -63.52 Mn |
| Jun 30, 2019 | -71.39 Mn |
| Mar 31, 2019 | -12.95 Mn |
| Dec 31, 2018 | -7.20 Mn |
| Sep 30, 2018 | -13.53 Mn |
| Jun 30, 2018 | -7.06 Mn |
| Mar 31, 2018 | -15.96 Mn |